![]() ![]() No available data support on-demand PrEP when HIV exposure occurs through vaginal exposure. Patients should be counseled to use additional HIV prevention strategies (e.g., condoms) for the first 20 days after initiating TDF/FTC PrEP and for 28 days after last potential vaginal exposure (BII). Providers should counsel patients about the importance of daily adherence to oral TDF/FTC PrEP to prevent HIV acquisition (AI).If a person receiving cabotegravir (CAB) PrEP becomes pregnant, the limited available safety data and long half-life of CAB should be discussed with the patient with shared decision-making, and the patient may benefit from expert consultation. For people with PrEP indications in pregnancy, CAB-LA dosing, efficacy, and safety remain unknown. Long-acting injectable cabotegravir (CAB-LA) is FDA approved for people with vaginal exposure to HIV.Risk for HIV acquisition should be reassessed, and people should be counseled regarding benefits and risks of PrEP use in pregnancy (AII). People who become pregnant while using TDF/FTC as PrEP can continue PrEP throughout their pregnancy. ![]() Food and Drug Administration (FDA)-approved PrEP option for HIV prevention with known safety and efficacy data in people with receptive vaginal exposure and with demonstrated safety in pregnancy. Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) is currently the U.S.Health care providers should offer PrEP to those who desire PrEP or have specific indications for PrEP use (e.g., injection drug use). Centers for Disease Control and Prevention (CDC) guidance recommends health care providers should discussPrEP with all sexually active people without HIV-including individuals who are trying to conceive, pregnant, postpartum, or breastfeeding-to prevent HIV acquisition (AII) counseling should include the benefits of PrEP to prevent HIV acquisition and perinatal transmission (AI) and potential adverse effects of PrEP during periconception, pregnancy, postpartum, and breastfeeding periods (AII). ![]()
0 Comments
Leave a Reply. |